Kathleen S Keegan Selected Research

Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)

1/2017

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kathleen S Keegan Research Topics

Disease

5	Neoplasms (Cancer) 01/2020 - 06/2014
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2018
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2017
1	Genomic Instability 06/2014

Drug/Important Bio-Agent (IBA)

2	Agammaglobulinaemia Tyrosine KinaseIBA 01/2020 - 01/2017
1	tirabrutinibIBA 01/2020
1	ibrutinibIBA 01/2020
1	venetoclaxIBA 12/2018
1	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2017
1	idelalisibIBA 01/2017
1	TensinsIBA 01/2017
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2017
1	ThiazolesIBA 06/2014
1	human CDC7 proteinIBA 06/2014
1	Phosphotransferases (Kinase)IBA 06/2014

Therapy/Procedure

1	Therapeutics 12/2018